FundaMental Pharma is a preclinical, seed stage biopharmaceutical company dedicated to removing barriers in treatment-resistant depression
FundaMental Pharma is a preclinical, seed stage biopharmaceutical company dedicated to removing barriers in treatment-resistant depression. They are developing novel, dual-acting NMDA receptor modulators for rapid and sustained relief for treatment-resistant depression (TRD) patients.